Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis

  • Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1
  • Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including no liver safety concerns1
  • Oral remibrutinib has potential to be first targeted therapy approved for CIndU, which affects estimated 29 million adults worldwide2,3
/by

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis

  • Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1
  • Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including no liver safety concerns1
  • Oral remibrutinib has potential to be first targeted therapy approved for CIndU, which affects estimated 29 million adults worldwide2,3
/by

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis

  • In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
  • Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1  
/by

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis

  • In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
  • Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1  
/by

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis

  • In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
  • Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1  
/by

Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List

Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
metzgma4

/by

What’s next in Neuroscience drug discovery

What’s next in Neuroscience drug discovery
hajdola1

/by

What’s next in Neuroscience drug discovery

What’s next in Neuroscience drug discovery
hajdola1

/by

What’s next in Neuroscience drug discovery

What’s next in Neuroscience drug discovery
hajdola1

/by

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
arcticnovartis

  • New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland
  • Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees
  • Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients

Basel, February 6, 2026 – Novartis today broke grou

/by